CERENAT病例对照研究中过敏性疾病与胶质瘤和脑膜瘤风险的关系
基于法国4个地区2004-2010年CERENAT多中心病例对照研究,分析273例胶质瘤、218例脑膜瘤和982例匹配对照。任何过敏史与胶质瘤风险呈显著负相关(OR 0.52,95%CI 0.36-0.75),与过敏性疾病数量呈剂量效应关系(p-trend=0.001),与花粉症/过敏性鼻炎关联尤为明显(OR 0.46,95%CI 0.30-0.72);脑膜瘤与总体或特定过敏性疾病均无关联。
要点
- 任何过敏史与胶质瘤风险显著负相关,OR 0.52(95%CI 0.36-0.75)。
- 胶质瘤风险与过敏性疾病数量呈剂量效应关系(p-trend=0.001)。
- 脑膜瘤与总体或特定过敏性疾病均无关联。
核心结论
- 研究结果证实过敏性疾病与胶质瘤风险呈负相关,但对过敏在脑膜瘤风险中的作用提出质疑。
- 未来研究需要阐明总体过敏和过敏性鼻炎对胶质瘤的生物学机制,并确认按性别不同的效应。
研究设计与样本
- CERENAT多中心病例对照研究,2004-2010年在法国4个地区开展。
- 共分析273例胶质瘤、218例脑膜瘤和982例从当地选民名册选取的匹配对照。
- 通过面对面访谈的详细问卷收集医生诊断的过敏性哮喘、湿疹、鼻炎/花粉症及其他过敏性疾病史。
- 采用匹配集的条件logistic回归,并调整受教育程度和手机使用。
主要发现
- 胶质瘤与任何过敏史呈显著负相关(OR 0.52,95%CI 0.36-0.75)。
- 胶质瘤风险与报告的过敏性疾病数量呈剂量效应关系(p-trend=0.001)。
- 胶质瘤与花粉症/过敏性鼻炎关联尤为强烈(OR 0.46,95%CI 0.30-0.72)。
- 与胶质瘤风险的关联在女性中更为明显。
- 脑膜瘤与总体或特定过敏性疾病均未观察到关联。
关键数值与推荐
- 胶质瘤与任何过敏史:OR 0.52(95%CI 0.36-0.75)。
- 胶质瘤与花粉症/过敏性鼻炎:OR 0.46(95%CI 0.30-0.72)。
- 胶质瘤与过敏性疾病数量的剂量效应:p-trend=0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究需要阐明总体过敏和过敏性鼻炎对胶质瘤的生物学机制,并确认按性别不同的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inverse association between allergic conditions and glioma risk has been consistently reported in epidemiological studies with little attention paid to potential environmental confounders; the association with meningioma risk is less consistent. We examined the association between allergy history and risk of glioma and meningioma in adults using data from the CERENAT (CEREbral tumors: a NATional study) multicenter case-control study carried out in 4 areas in France in 2004-2010. Participants' histories of doctor-diagnosed allergic asthma, eczema, rhinitis/hay fever and other allergic conditions were collected at onset through a detailed questionnaire delivered in a face-to-face interview. Conditional logistic regression for matched sets was adjusted for participants' educational level and mobile phone use. A total of 273 glioma cases, 218 meningioma cases and 982 matched controls selected from the local electoral rolls were analyzed. A significant inverse association was found between glioma and a history of any allergy (OR 0.52, 95% CI 0.36-0.75), with a dose-effect relationship with the number of allergic conditions reported (p-trend = 0.001) and a particularly strong association with hay fever/allergic rhinitis (OR 0.46, 95% CI 0.30-0.72). Interestingly, associations with glioma risk were more pronounced in women. For meningioma, no association was observed with overall or specific allergic conditions. Our findings confirmed the inverse association between allergic conditions and glioma risk but questioned the role of allergy in meningioma risk. Future research is needed to clarify the biological mechanism of overall allergy and allergic rhinitis on glioma and to confirm the different effect by gender.
引用
- Pouchieu C, Raherison C, Piel C, et al. Allergic conditions and risk of glioma and meningioma in the CERENAT case-control study. J Neurooncol. 2018. PMID: 29500663. doi:10.1007/s11060-018-2816-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。